Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.42 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | TDO2 | P48775 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.41 |
| ▸ | GBA1 | P04062 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | CFD | P00746 | 1/20 | 0.39 |
| ▸ | TPSB2 | P20231 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20445783 | 1.00 | HDAC4 (0.42) | HDAC4HDAC7HDAC5IDO1TDO2 | |
| SCHEMBL25196113 | 0.89 | HDAC4 (0.40) | HDAC4HDAC7HDAC5IDO1TDO2 | |
| SCHEMBL25196114 | 0.89 | HDAC4 (0.40) | HDAC4HDAC7HDAC5IDO1TDO2 | |
| SCHEMBL30800833 | 0.85 | HDAC4 (0.44) | HDAC4HDAC7HDAC5IDO1TDO2 | |
| SCHEMBL30559591 | 0.85 | HDAC4 (0.44) | HDAC4HDAC7HDAC5IDO1TDO2 | |
| SCHEMBL8513883 | 0.85 | HDAC4 (0.44) | HDAC4HDAC7HDAC5IDO1TDO2 | |
| SCHEMBL432890 | 0.85 | HDAC4 (0.44) | HDAC4HDAC7HDAC5IDO1TDO2 | |
| SCHEMBL1464027 | 0.85 | HDAC4 (0.44) | HDAC4HDAC7HDAC5IDO1TDO2 | |
| SCHEMBL30818125 | 0.85 | HDAC4 (0.44) | HDAC4HDAC7HDAC5IDO1TDO2 | |
| SCHEMBL11084543 | 0.85 | TAAR1 (0.47) | HDAC4HDAC7HDAC5IDO1TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11345678-B2 | Benzopyrazole compound used as RHO kinase inhibitor | MEDSHINE DISCOVERY INC. (CN) | 2022-05-31 | — | — | US | disclosed |
| US-20210371393-A1 | BENZOPYRAZOLE COMPOUND USED AS RHO KINASE INHIBITOR | MEDSHINE DISCOVERY INC. (CN) | 2021-12-02 | — | — | US | disclosed |
| EP-3356348-B1 | 2-AMINOQUINAZOLINE DERIVATIVES AS P70S6 KINASE INHIBITORS | SENTINEL ONCOLOGY LTD (GB) | 2021-05-05 | — | — | EP | disclosed |
| EP-3782987-A1 | BENZOPYRAZOLE COMPOUND USED AS RHO KINASE INHIBITOR | Medshine Discovery Inc. (CN) | 2021-02-24 | — | — | EP | disclosed |
| CN-108473472-B | 2-aminoquinazoline derivatives as P70S6kinase inhibitors | 圣提内尔肿瘤学有限公司 | 2021-02-12 | — | — | CN | disclosed |
| US-10730882-B2 | 2-aminoquinazoline derivatives as P70S6 kinase inhibitors | SENTINEL ONCOLOGY LIMITED (GB) | 2020-08-04 | — | — | US | disclosed |
| WO-2019201297-A1 | BENZOPYRAZOLE COMPOUND USED AS RHO KINASE INHIBITOR | 南京明德新药研发有限公司 | 2019-10-24 | — | — | WO | disclosed |
| WO-2019201296-A1 | PYRAZOLE COMPOUND USED AS RHO KINASE INHIBITOR | 南京明德新药研发有限公司 | 2019-10-24 | — | — | WO | disclosed |
| US-20190292195-A1 | 2-AMINOQUINAZOLINE DERIVATIVES AS P70S6 KINASE INHIBITORS | SENTINEL ONCOLOGY LIMITED (GB) | 2019-09-26 | — | — | US | disclosed |
| US-10344033-B2 | 2-aminoquinazoline derivatives as P70S6 kinase inhibitors | SENTINEL ONCOLOGY LIMITED (GB) | 2019-07-09 | — | — | US | disclosed |
| US-20180370975-A1 | 2-AMINOQUINAZOLINE DERIVATIVES AS P70S6 KINASE INHIBITORS | SENTINEL ONCOLOGY LIMITED (GB) | 2018-12-27 | — | — | US | disclosed |
| EP-3356348-A1 | 2-AMINOQUINAZOLINE DERIVATIVES AS P70S6 KINASE INHIBITORS | Sentinel Oncology Limited (GB) | 2018-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292195-A1 | 2-AMINOQUINAZOLINE DERIVATIVES AS P70S6 KINASE INHIBITORS | RPS6KA1, MTOR, RPTOR | HDAC4 1387/4885HDAC7 1211/4885HDAC5 800/4885 |
| US-20180370975-A1 | 2-AMINOQUINAZOLINE DERIVATIVES AS P70S6 KINASE INHIBITORS | RPS6KA1, MTOR, RPTOR | HDAC4 1387/4885HDAC7 1211/4885HDAC5 800/4885 |
| US-10344033-B2 | 2-aminoquinazoline derivatives as P70S6 kinase inhibitors | RPS6KA1, MTOR, RPTOR | HDAC4 1387/4885HDAC7 1211/4885HDAC5 800/4885 |
| US-11345678-B2 | Benzopyrazole compound used as RHO kinase inhibitor | ROCK1, ROCK2, CIT | HDAC4 1036/4885HDAC7 614/4885HDAC5 600/4885 |
| US-10730882-B2 | 2-aminoquinazoline derivatives as P70S6 kinase inhibitors | RPS6KA1, MTOR, RPTOR | HDAC4 1387/4885HDAC7 1211/4885HDAC5 800/4885 |
| US-20210371393-A1 | BENZOPYRAZOLE COMPOUND USED AS RHO KINASE INHIBITOR | ROCK1, ROCK2, CIT | HDAC4 1036/4885HDAC7 614/4885HDAC5 600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.